Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, H. pylori negative status (by Urea Breath Test)~* Male or female subjects~* Age 18-55 years~* Able to tolerate the placement of a nasogastric pH probe at screening~* Baseline Gastric pH≤2~* Use of acceptable form of birth control in females with child-bearing potential~* Had not used any form of tobacco (e.g. smoking or chewing) for the last year~* Can swallow a size 00 capsule without difficulty~* Willing to comply with study protocol~* Signed Informed Consent form~Exclusion Criteria:~* BMI \> 40~* Slow or poor Omeprazole metabolizers (heterozygous or homozygous, respectively) based on CYP2C19 genotyping test.~* Any significant history of / or concurrent gastrointestinal diseases or conditions such as:~  * GERD~ * Acute gastrointestinal bleeding~ * Zollinger Ellison Syndrome or Gastric hypersecretory condition~ * Known Barrett's esophagus~ * Esophageal stricture~ * Peptic ulcer disease (gastric or duodenal) or family history of peptic ulcer disease~ * Gastric outlet obstruction~ * Gastroparesis~* Significant medical history or concurrent illness as determined by the principal investigator~* Any medical disorder that alters the normal gastric acid secretion profile as determined by the principal investigator~* History of diabetes mellitus~* Significant laboratory abnormalities as determined by the principal investigator~* Known metabolic alkalosis, hypocalcemia, sodium restricted diet, hypokalemia, respiratory alkalosis~* Pregnant or lactating women~* Had been treated with any investigational drug or therapy or participated in a clinical trial within 30 days prior to entering the trial~* Use of any medication other than contraception or hormone replacement therapy; OTC drugs other than vitamins or occasional acetaminophen within 30 days prior to entering the trial or during the trial~* Use of NSAID medications within 30 days prior to entering the trial (e.g. Ibuprofen, Aspirin, Naproxen etc)~* Positive urine test for alcohol or other drugs~* Concurrent use of gastric anti-secretory drugs such as defined below:~  * Use of a PPI 30 days prior to each stage or during the trial~ * Use of H2RA 14 days prior to each stage or during the trial~ * Concurrent use of antacids (including over-the-counter) 24 hours prior to each stage or during the trial~* Use of any medication that modifies gastric acid secretion 30 days prior to or during the trial.~* Had ingested grapefruit within 14 days of dose administration in any trial period~* Significant drug allergy or known hypersensitivity to any of the ingredients in the trial drugs Omeprazole, Succinic Acid or to Lidocaine~* Consumption of coffee within 48 hours of dose administration in any trial period.~* Had donated blood within 30 days of entering the trial~* Known positive serology for HBV, HCV or HIV~* Any reason which makes the subject a poor candidate based on the physician's discretion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Omeprazole 20 mg (Type: ACTIVE_COMPARATOR): None
- Vecam 20/300 (Type: EXPERIMENTAL): None
- Vecam 40/300 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).